Cadila Pharmaceuticals has introduced the Cadiflu Tetra Vaccine, an advanced Quadrivalent Influenza Vaccine designed to combat influenza, a recurrent and widespread viral infection. The vaccine has received approval from the Drug Controller General of India (DCGI) for use in both adults and children.

The Cadiflu Tetra Vaccine targets four strains of the Influenza virus subtype–A and B, responsible for seasonal epidemics. Utilizing cutting-edge proprietary technology involving Nano-sized particles, the vaccine mimics the external structure of the virus without containing intact genetic material.

The vaccine contains hemagglutinin (HA), neuraminidase (NA), and matrix1 (M1) proteins from the respective strains aggregated in a single formulation. Notably, the vaccine is a virus-like particle (VLP) vaccine that replicates the external structure of viruses but lacks live genetic material, enhancing its safety profile.

Dr. Rajiv I. Modi, Chairman and Managing Director of Cadila Pharmaceuticals, expressed the company's commitment to advancing healthcare through the development of the Cadiflu Tetra Vaccine. He emphasized the goal of providing a robust solution to protect vulnerable populations and strengthen public health defenses against influenza outbreaks globally.

The Cadiflu Tetra Vaccine aims to reduce the incidence of influenza illness, alleviate disease severity, and lower the transmission of the infection. Additionally, the vaccine holds promise for enhancing the protection of pregnant women against influenza, contributing to the overall well-being of both mother and child.

Influenza, commonly known as seasonal flu, is a highly contagious acute respiratory illness caused by influenza viruses. Given its global impact and potential for multiple waves throughout the year, the introduction of the Cadiflu Tetra Vaccine marks a significant breakthrough in vaccine development to address this public health concern.